Archive · 2 Jan 2026
India Rises to 8th in WHO Pharmacovigilance Rankings
India has made a big improvement in how it reports and monitors medicine safety to the World Health Organization.
It has moved from the 123rd position to the 8th position in just a few years.
The health minister, Mr. Nadda, released a new book called the Indian Pharmacopoeia 2026, which has rules and standards for medicines.
This book now has more rules for important medicines like those for tuberculosis, diabetes, cancer, and iron supplements.
It also has new rules for blood products.
The Indian Pharmacopoeia is now accepted in 19 countries, showing that India is becoming a leader in making and regulating medicines.
India has risen from 123rd to 8th in WHO pharmacovigilance contributions.
The Indian Pharmacopoeia 2026, the 10th edition, was released by Union Health Minister J. P. Nadda.
The new edition includes 121 new monographs, totaling 3,340 monographs.
It strengthens standards for key therapeutic categories like anti-tubercular, anti-diabetic, and anti-cancer medicines.
The Indian Pharmacopoeia is now recognized in 19 countries of the global south.
- Who
- Union Health Minister J. P. Nadda
- What
- Release of Indian Pharmacopoeia 2026 and India's rise in WHO pharmacovigilance rankings
- When
- Friday (specific date not mentioned)
- Where
- Dr. Ambedkar International Centre, New Delhi
- Why
- To strengthen drug standards and pharmacovigilance in India
- Current WHO Ranking
- 8th
- Previous WHO Ranking (2009-2014)
- 123rd
- New Monographs in IP 2026
- 121
- Total Monographs in IP 2026
- 3,340
- Countries Recognizing Indian Pharmacopoeia
- 19
- New Blood Component Monographs
- 20